XML 102 R56.htm IDEA: XBRL DOCUMENT v3.25.2

Moderna Collaboration and License Agreement - Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations (Details) - USD ($) $ in Thousands	Mar. 31, 2025	Dec. 31, 2024
Performance obligations:
Research and development		$ 35,301
Option rights	$ 41,250	41,250
Total performance obligations		$ 76,551

X

- Definition

Amount of transaction price allocated to option rights performance obligation that has not been recognized as revenue.

+ References

No definition available.

+ Details

Name:	carm_RevenueRemainingPerformanceObligationOptionRightsAmount
Namespace Prefix:	carm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Amount of transaction price allocated to research and development performance obligation that has not been recognized as revenue.

+ References

No definition available.

+ Details

Name:	carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount
Namespace Prefix:	carm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenuePerformanceObligationAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of transaction price allocated to performance obligation that has not been recognized as revenue.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (a)
-SubTopic 10
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-13

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant